Alcoholic liver disease secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Alcoholic liver disease}}
{{Alcoholic liver disease}}
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{CMG}}; {{AE}} {{MKA}}


{{CMG}}
==Overview==
==Overview==
One should discuss the alcohol intake with the doctor. The doctor can counsel about how much alcohol is safe to drink.
Effective measures for the [[secondary prevention]] of alcoholic liver disease include abstinence. Abstinence can be achieved through drug therapies in an inpatient as well as an out patient setting.
 
==Secondary Prevention==
 
*Effective measures for the [[secondary prevention]] of alcoholic liver disease include:<ref name="pmid19489992">{{cite journal |vauthors=Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N |title=The effectiveness of brief alcohol interventions in primary care settings: a systematic review |journal=Drug Alcohol Rev |volume=28 |issue=3 |pages=301–23 |year=2009 |pmid=19489992 |doi=10.1111/j.1465-3362.2009.00071.x |url=}}</ref><ref name="pmid8925349">{{cite journal |vauthors=Moos RH, King MJ, Patterson MA |title=Outcomes of residential treatment of substance abuse in hospital- and community-based programs |journal=Psychiatr Serv |volume=47 |issue=1 |pages=68–74 |year=1996 |pmid=8925349 |doi=10.1176/ps.47.1.68 |url=}}</ref><ref name="pmid15200577">{{cite journal |vauthors=Bouza C, Angeles M, Magro A, Muñoz A, Amate JM |title=Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review |journal=Addiction |volume=99 |issue=7 |pages=811–28 |year=2004 |pmid=15200577 |doi=10.1111/j.1360-0443.2004.00763.x |url=}}</ref><ref name="pmid10208148">{{cite journal |vauthors=Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT |title=Pharmacological treatment of alcohol dependence: a review of the evidence |journal=JAMA |volume=281 |issue=14 |pages=1318–25 |year=1999 |pmid=10208148 |doi= |url=}}</ref><ref name="pmid19630744">{{cite journal |vauthors=Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM |title=Review of topiramate: an antiepileptic for the treatment of alcohol dependence |journal=Curr Drug Abuse Rev |volume=2 |issue=2 |pages=135–42 |year=2009 |pmid=19630744 |doi= |url=}}</ref><ref name="pmid18068515">{{cite journal |vauthors=Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G |title=Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study |journal=Lancet |volume=370 |issue=9603 |pages=1915–22 |year=2007 |pmid=18068515 |doi=10.1016/S0140-6736(07)61814-5 |url=}}</ref><ref name="pmid7672043">{{cite journal |vauthors=Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F |title=The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease |journal=Eur. J. Epidemiol. |volume=10 |issue=6 |pages=657–64 |year=1994 |pmid=7672043 |doi= |url=}}</ref><ref name="pmid1476147">{{cite journal |vauthors=Klatsky AL, Armstrong MA |title=Alcohol, smoking, coffee, and cirrhosis |journal=Am. J. Epidemiol. |volume=136 |issue=10 |pages=1248–57 |year=1992 |pmid=1476147 |doi= |url=}}</ref><ref name="pmid8985274">{{cite journal |vauthors=Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC |title=Excess weight risk factor for alcoholic liver disease |journal=Hepatology |volume=25 |issue=1 |pages=108–11 |year=1997 |pmid=8985274 |doi=10.1002/hep.510250120 |url=}}</ref>
**[[Naltrexone]] or [[acamprosate]] to prevent relapse
**[[Disulfiram]] and [[topiramate]] for decreasing craving and [[withdrawal symptoms]]
**[[Smoking cessation]] and [[weight loss]] where indicated
 
==References==
==References==
{{reflist|2}}
{{reflist|2}}
 
{{WS}}
{{WH}}
{{WH}}
{{WS}}


[[Category:Needs content]]
[[Category:Surgery]]
[[Category:Pathology]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Alcohol abuse]]
[[Category:Up-To-Date]]
[[Category:Hepatology]]
[[Category:Hepatology]]
[[Category:Medicine]]

Latest revision as of 20:20, 29 July 2020

Alcoholic liver disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alcoholic liver disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alcoholic liver disease secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alcoholic liver disease secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alcoholic liver disease secondary prevention

CDC on Alcoholic liver disease secondary prevention

Alcoholic liver disease secondary prevention in the news

Blogs on Alcoholic liver disease secondary prevention

Directions to Hospitals Treating Alcoholic liver disease

Risk calculators and risk factors for Alcoholic liver disease secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

Effective measures for the secondary prevention of alcoholic liver disease include abstinence. Abstinence can be achieved through drug therapies in an inpatient as well as an out patient setting.

Secondary Prevention

References

  1. Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N (2009). "The effectiveness of brief alcohol interventions in primary care settings: a systematic review". Drug Alcohol Rev. 28 (3): 301–23. doi:10.1111/j.1465-3362.2009.00071.x. PMID 19489992.
  2. Moos RH, King MJ, Patterson MA (1996). "Outcomes of residential treatment of substance abuse in hospital- and community-based programs". Psychiatr Serv. 47 (1): 68–74. doi:10.1176/ps.47.1.68. PMID 8925349.
  3. Bouza C, Angeles M, Magro A, Muñoz A, Amate JM (2004). "Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review". Addiction. 99 (7): 811–28. doi:10.1111/j.1360-0443.2004.00763.x. PMID 15200577.
  4. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT (1999). "Pharmacological treatment of alcohol dependence: a review of the evidence". JAMA. 281 (14): 1318–25. PMID 10208148.
  5. Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM (2009). "Review of topiramate: an antiepileptic for the treatment of alcohol dependence". Curr Drug Abuse Rev. 2 (2): 135–42. PMID 19630744.
  6. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007). "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study". Lancet. 370 (9603): 1915–22. doi:10.1016/S0140-6736(07)61814-5. PMID 18068515.
  7. Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F (1994). "The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease". Eur. J. Epidemiol. 10 (6): 657–64. PMID 7672043.
  8. Klatsky AL, Armstrong MA (1992). "Alcohol, smoking, coffee, and cirrhosis". Am. J. Epidemiol. 136 (10): 1248–57. PMID 1476147.
  9. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC (1997). "Excess weight risk factor for alcoholic liver disease". Hepatology. 25 (1): 108–11. doi:10.1002/hep.510250120. PMID 8985274.

Template:WS Template:WH